We bring you the summary of the most relevant:
Wednesday May 12
Pfizer will ask in Mexico to use its vaccine in children between 12 and 15 years of age
The Pfizer laboratory announced that it will request the Federal Commission for the Protection against Sanitary Risks (Cofepris) authorization for the use of its vaccine against Covid-19 in minors between 12 and 15 years of age. The Secretary of Foreign Relations, Marcelo Ebrard, confirmed the announcement and indicated that Pfizer’s request will be delivered in the next few days. This Monday, the US FDA authorized the use of Pfizer’s vaccine for this age group, and the EMA, the European regulatory body, is in the process of analyzing its possible application.
I share with you the good news that Pfizer will submit the vaccine applicable to minors between 12 and 15 years of age for authorization by COFEPRIS in the next few days: pic.twitter.com/ElF9PSuhGv
– Marcelo Ebrard C. (@m_ebrard) May 12, 2021
Vaccination for pregnant women begins in CDMX
This Wednesday the vaccination against Covid-19 for pregnant women begins in Mexico City, specifically in the Cuauhtémoc mayor’s office. This sector of the population is now part of the priority groups for the Ministry of Health, to receive immunization. According to the director general of the National Center for Preventive Programs and Disease Control (Cenaprece), Ruy López Ridaura, the SARS-CoV-2 infection is more serious during pregnancy. Registration on the site mivacuna.salud.gob.mx is open from Tuesday for pregnant women.
Daily Technical Release: New Coronavirus in the World # COVID19 | May 11, 2021
➡️ https://t.co/cfLnynGF0J pic.twitter.com/MtxdQLCwyw
– SALUD México (@SSalud_mx) May 12, 2021
The Indian variant of covid-19 is present in 44 countries
The World Health Organization (WHO) said on Wednesday that the variant of covid-19 that has caused the recent explosion of infections in India is present in at least 44 countries around the world. The highest world health authority assured that Covid-19 variant B.1.617, which was found for the first time in India in October, has been detected in sequences incorporated into the GISAID database “in 44 countries in the six WHO regions “, and specified that it has received” reports that it has been detected in five other countries. ” (AFP)
Tuesday May 11
New website will concentrate data on vaccination
The Ministry of Health announced the start-up of a new website in which all the information on vaccination against Covid-19 in Mexico will be concentrated. The new Covid Vaccine site will offer all the data that the population needs to know about inoculation and registration procedures. The website can be consulted at vaccinacovid.gob.mx. The site mivacuna.salud.gob.mx will continue to be the official platform for registration in the national vaccination process.
Daily Technical Release: New Coronavirus in the World # COVID19 | May 10, 2021
➡️ https://t.co/EgzEJoWaK2 pic.twitter.com/eVmwXsYrnf
– SALUD México (@SSalud_mx) May 11, 2021
FDA Authorizes Pfizer Vaccine for Children 12-15 Years
The United States drug agency (FDA) announced on Monday that it authorized the Pfizer / BioNTech Covid-19 vaccine for minors between the ages of 12 and 15. The measure is “an important step in the fight against the pandemic” and “allows a younger population to be protected against Covid-19,” said Janet Woodcock, acting head of the FDA, in a statement. Until now, the emergency use of this vaccine was authorized for people from 16 years of age. Now it can be given to millions more adolescents in two injections containing the same dose as the adult vaccine. (AFP)
Today, FDA expanded the EUA for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of # COVID19 to include adolescents 12-15 years of age. FDA amended the EUA issued on Dec. 11, 2020 for administration in individuals 16 years of age and older. https://t.co/3ROLW8WXwL pic.twitter.com/d9zwg7BS4q
– US FDA (@US_FDA) May 10, 2021
Novavax delays authorization request for its vaccine
US biotech firm Novavax said on Monday it had delayed its plans to seek clearance for its Covid-19 vaccine candidate, a setback for developing countries who hope the immunizer will be available soon. The laboratory expects to request authorization in the United States and Europe in the third quarter of 2021, according to a statement that caused a 12% drop in its shares. Novavax’s vaccine is key to the World Health Organization (WHO) Covax program, which was created to try to ensure that poor countries have equitable access to immunizers to fight the coronavirus pandemic. (AFP)
Monday May 10
40% of maternal deaths in 2021 by Covid-19
At least 40% of the 133 maternal deaths that have occurred in 2021 in Mexico are due to Covid-19, reported the Ministry of Health. “40% of the 133 maternal deaths in Mexico in 2021 have been caused by Covid-19,” Gabriela Nucamendi, director of epidemiological surveillance of non-communicable diseases of the Secretariat, said at a press conference. (EFE)
This may interest you: What is it like to be a mother in times of Covid-19?
The WHO classifies the variant discovered in India as “worrying”
The World Health Organization (WHO) said on Monday that it classified the variant of the covid-19 virus discovered in India, B.1.617, as “worrying” because it is more resistant and contagious. “There are reports that B.1.617 is more contagious,” but there are also indications that it has a degree of resistance to vaccines, and “therefore, we classify it as a worrying variant,” said Dr. Maria Van Kerkhove, technical manager of the fight against Covid-19 at the WHO. (AFP)
Cuba will begin mass inoculation in Havana
Cuba will carry out from next week in Havana a study of population health intervention with its vaccine candidates Abdala and Soberana 02 against covid-19, which will be administered to more than 1.7 million inhabitants of the capital. The Minister of Public Health (Minsap), José Ángel Portal, explained during an appearance on state television that this study will be carried out after having applied 415,161 doses of both vaccine candidates in the different phases of clinical trials and intervention studies in which support a low incidence of adverse events and a good immune response. (EFE)